Mechanisms of astragalus in treating chronic kidney disease and delaying renal cellular senescence

doi:10.3877/cma.j.issn.2095-3216.2014.06.009

Abstract

Abstract:

This paper is aimed to discuss about the mechanisms of astragalus in treating chronic kidney disease and delaying renal cellular senescence, including immune regulation, anti-inflammation,reduction of proteinuria and hyperlipidemia, diuresis and natriuresis, regulation of electrolyte disorders,delaying renal fibrosis, anti-oxidation, and anti-apoptosis. Renal cellular senescence may be associated with intracellular oxygen radicals, cellular telomere length and enzyme activity, and aging-related genes such as p16 gene. It has been suggested that astragalus is expected to be a Chinese medicine that can delay the renal cellular senescence.

Key words: Astragalus, Chronic kidney disease, Cellular senescence

Hong Liu, Wei Sun, Liubao Gu, Yue Tu, Hao Hu. Mechanisms of astragalus in treating chronic kidney disease and delaying renal cellular senescence[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(06): 328-331.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.06.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I06/328

References 45

1	Ko JK, Lam FY, Cheung AP. Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis [J]. World J Gastroenterol, 2005, 11(37): 5787-5794.
2	Chen RF, Shao H, Lin SQ, et al. Treatment with Astragalus membranaceus produces antioxidative effects and attenuates intestinal mucosa injury induced by intestinal ischemia-reperfusion in rats[J]. Am J Chin Med, 2011, 39(5): 879-887.
3	Lei H, Wang B, Li WP, et al. Anti-aging effect of astragalosides and its mechanism of action [J]. Acta Pharmacol Sin, 2003, 24(3): 230-234.
4	Qin QJ, Niu JY, Wang ZX, et al. Astragalus membranaceus inhibits inflammation via phospho-P38 mitogen-activated protein kinase(MAPK) and nuclear factor (NF)-kappa B pathways in advanced glycation end product-stimulated macrophages [J]. Int J Mol Sci,2012, 13(7): 8379-8387.
5	Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of astragalus membranaceus [J]. Cancer Lett, 2007, 252(1): 43-54.
6	Ma X, Zhang K, Li HX, et al. Extracts from Astragalus membranaceus limit myocardial cell death and improve cardiac function in a rat model of myocardial ischemia [ J ]. J Ethnopharmacol, 2013, 149(3): 720-728.
7	Jia W, Gao WY, Tang LD. Antidiabetic herbal drugs officially approved in China [J]. Phytother Res, 2003, 17(10): 1127-1134.
8	Zhang WD, Chen H, Zhang C, et al. Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro [J]. Planta Med, 2006, 72(1): 4-8.
9	Gui SY, Wei W, Wang H, et al. Effects and mechanisms of crude astragalosides fraction on liver fibrosis in rats [ J ].J Ethnopharmacol, 2006, 103(2): 154-159.
10	Li X, He DL, Zhang LL, et al. A novel antioxidant agent,astragalosides, prevents shock wave-induced renal oxidative injury in rabbits [J]. Urol Res, 2006, 34(4): 277-282.
11	Qi WW, Niu JY, Qin QJ, et al. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells [J]. Cell Stress Chaperones, 2014, 19(1): 105-114.
12	徐凌. 黄芪的药理作用及临床应用[J]. 现代医药卫生,2009,25(21):3312-3313.
13	Peng A, Gu Y, Gui DK, et al. Aqueous extract of astragali radix induces human natriuresis through enhancement of renal response to atrial natriuretic peptide [J]. J Ethnopharmacol, 2008, 116(3):413-421.
14	崔冰,姚孟英,陶雅非. 黄芪注射液对慢性肾衰竭病人肾功能及内皮素的影响[J]. 中国中西医结合肾病杂志,2005, 6(3):166-167.
15	盛梅笑,孙伟,江燕,等. 含黄芪腹透液对高腹膜转运CAPD 患者超滤功能的影响[J]. 中国中西医结合肾病杂志,2007, 8(4):205-208.
16	邱世翠,李波清,刘金荣,等. 黄芪对小鼠免疫功能的影响[J].时珍国医国药,2000, 11(5):389-390.
17	于力, 卓美瑛, 杨小苏, 等. 黄芪注射液对肾病综合征细胞因子及其基因表达的影响[J]. 中国中西医结合肾病杂志, 2001, 2(9): 523-524.
18	朱雪萍,王新华,林吉祥,等. 黄芪注射液对透析患者免疫功能的作用[J]. 实用中医内科杂志,2001,15(1):9-10.
19	夏春英,陈力,赵亚清,等. 黄芪对慢性肾炎的红细胞免疫功能及白细胞介素-6 的影响[J]. 中华肾脏病杂志,1998,14(5):321.
20	Wang YP, Li XY, Song CQ, et al. Effect of astragaloside IV on T,B lymphocyte proliferation and peritoneal macrophage function in mice [J]. Acta Pharmacol Sin, 2002, 23(3): 263-266.
21	Tan SF, Wang GF, Guo YP, et al. Preventive Effects of a natural anti-inflammatory agent, astragaloside IV, on ischemic acute kidney injury in rats [J]. Evid Based Complement Alternat Med, 2013,2013: 284025.
22	是俊凤,朱汉威,张翀,等. 黄芪注射液治疗慢性肾小球肾炎的观察[J]. 上海第二医科大学学报,2002,22(3):245-248.
23	陈其元. 黄芪对肾性蛋白尿的治疗作用[J]. 时珍国医国药,2001,12(11):1016-1017.
24	许俊福,郭庆祝,宋嘉耕,等. 黄芪、川芎嗪治疗原发性肾病综合征临床分析[J]. 内蒙古民族大学学报,2002,17(2):151-152.
25	王海燕,李惊子,潘缉圣,等. 中药黄芪当归合剂对肾病综合征肾损伤的保护作用及对代谢紊乱的影响[J]. 北京大学学报(医学版),2002,34(5):542-552.
26	马骥,彭艾,陈靖,等. 黄芪对肾病综合征与充血性心力衰竭时血管加压素系统异常的不同改善作用[J]. 中华肾脏病杂志,1996,12(1):15-19.
27	丁炜,李惊子,邹万忠,等. 黄芪当归合剂对肾病综合征鼠肾转化生长因子β1 的影响[J]. 中华肾脏病杂志,1998,14(4):229-232.
28	闵亚丽,俞雷,衣利,等. 黄芪当归在肾小管间质纤维化大鼠模型中的作用[J]. 贵阳医学院学报,2003,28(2):134-136.
29	余凌,张俊峰,李惊子,等. 黄芪当归合剂防治肾病综合征鼠进行性肾小管间质损伤[J]. 中华肾脏病杂志,2000,16(5):283-286.
30	Meng L, Qu L, Tang J, et al. A combination of Chinese herbs,Astragalus membranaceus var. mongholicus and angelica sinensis,enhanced nitric oxide production in obstructed rat kidney [J].Vascul Pharmacol, 2007, 47(2-3): 174-183.
31	Meng LQ, Tang JW, Wang Y, et al. Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy [J]. Br J Pharmacol, 2011, 162(8):1805-1818.
32	方雅秀,陈晓春. 线粒体氧自由基与衰老的关系[J]. 国外医学(老年医学分册), 2006, 27(1): 24-28.
33	Gui DK, Huang JH, Liu W, et al. Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways [J]. Apoptosis, 2013, 18(4): 409-422.
34	Gui DK, Guo YP, Wang F, et al. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo [J]. PLoS One, 2012, 7(6): e39824.
35	Chen JG, Gui DK, Chen YF, et al. Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via alpha3beta1 integrin upregulation and integrin-linked kinase inhibition [J].Biochem Pharmacol, 2008, 76(6): 796-804.
36	Buemi M, Nostro L, Aloisi C, et al. Kidney aging: from phenotype to genetics [J]. Rejuvenation Res, 2005, 8(2): 101-109.
37	Nystrom T. The free-radical hypothesis of aging goes prokaryotic[J]. Cell Mol Life Sci, 2003, 60(7): 1333-1341.
38	Di Donna S, Mamchaoui K, Cooper RN, et al. Telomerase can extend the proliferative capacity of human myoblasts, but does not lead to their immortalization [J]. Mol Cancer Res, 2003, 1(9):643-653.
39	Melk A, Ramassar V, Helms LM, et al. Telomere shortening in kidneys with age [J]. J Am Soc Nephrol, 2000, 11(3): 444-453.
40	赵岚,李双杰,陈瑞珍,等. 端粒酶在病毒性心肌炎中的作用及黄芪甲甙干预研究[J]. 中国临床医学,2006,13(5):714-716.
41	Kuilman T, Michaloglou C, Mooi WJ, et al. The essence of senescence [J]. Genes Dev, 2010, 24(22): 2463-2479.
42	Famulski KS, Halloran PF. Molecular events in kidney ageing [J].Curr Opin Nephrol Hypertens, 2005, 14(3): 243-248.
43	Chkhotua AB, Abendroth D, Froeba G, et al. Up-regulation of cell cycle regulatory genes after renal ischemia/reperfusion: differential expression of p16(INK4a), p21(WAF1/CIP1) and p27(Kip1)cyclin-dependent kinase inhibitor genes depending on reperfusion time [J]. Transpl Int, 2006, 19(1): 72-77.
44	Hochegger K, Koppelstaetter C, Tagwerker A, et al. p21 and mTERT are novel markers for determining different ischemic time periods in renal ischemia-reperfusion injury [J]. Am J Physiol Renal Physiol, 2007, 292(2): F762-F768.
45	王培昌,张建,张宗玉,等. 黄芪碱化合物HDTIC-1 和2 对衰老相关基因p16 和p21 表达的影响[J]. 首都医科大学学报,2007,28(2):145-149.

[1]	Xiaoqing Tang, Ping He, You Yang, Xia Luo, Juying Zhang, Xin Yang, Jinhong Yu. Correlation of sound touch elastography combined with pulsed wave Doppler ultrasound imaging parameters with stage of early chronic kidney disease and their clinical significance [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(05): 491-499.
[2]	Siping Hu, Xingyu Xiong, Hang Xu, Lu Yang. The mechanisms of senescence-associated secretory phenotype factors in the occurrence and progression of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 425-434.
[3]	Shuxun Ling, Yue Tu, Siyi Liu. Visualization analysis on knowledge map of mesenchymal stem cells in the research field of chronic kidney disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(02): 73-82.
[4]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association. Clinical practice guidelines for kidney injury management of liver transplant recipients in China(2023 edition) [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(03): 276-288.
[5]	Bokai Cheng, Guang Yang. Progress of research on application of hyperinsulinemic-euglycemic clamp technique for assessing insulin resistance in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 334-339.
[6]	Junnan Guo, Hui Lin, Yilin Ren, Xi Qiao. Progress of research on the role of amino acid metabolism disturbance in the transition from AKI to CKD [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 283-287.
[7]	Rongrong Feng, Xiaole Su, Lihua Wang. Research progress on biological markers related to complication of cardiovascular disease in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 273-278.
[8]	Xiaolong Wang, Jie Wu, Shuwei Duan, Chaohui Wang, Na Pan, Yuanyuan Bai, Hangtian Li, Guangyan Cai. Effect of different levels of physical activity on the prognosis of patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(03): 121-128.
[9]	Yinan Zhang, Guozhen Zhu. Research progress on the transition from acute kidney injury to chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 106-112.
[10]	Yansheng Wu, Xianwen Zhang, Lin Wang. Research progress on the relationship between intestinal microecology and immunity in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 101-105.
[11]	Jinyi Zhang, Yuehong Li. Research progress on the efficacy and strategy of SARS-CoV-2 vaccination in patients with chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 97-100.
[12]	Wuhao Xiao, Kanghan Liu. Research progress on the treatment of osteoporosis in patients with advanced chronic kidney disease [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(02): 92-96.
[13]	Peipei Xi, Jiajun Zhou. Progress in research of sarcopenia in patients with chronic kidney disease: pathogenesis, diagnosis, and treatment [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 491-495.
[14]	Meiju Wei, Ling Pan. Role of gut microbiota-bile acid metabolism axis in chronic kidney disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 219-222.
[15]	Chao Wang, Hao Wang, Bai Sun, Ye Yuan, Weiguang Qiang, Hongbing Shi. The pro-apoptotic effect of carfilzomib combined with iodine-125 seed irradiation on KYSE-150 esophageal cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(02): 106-113.

Please choose a citation manager

Content to export